Listed

Asston Pharmaceuticals Ltd. IPO

Asston Pharmaceuticals Ltd, a Navi Mumbai-based pharmaceutical and nutraceutical manufacturer, is launching its IPO on July 9, with shares priced between ₹115 and ₹123. The company aims to raise ₹27.56 crore through a fresh issue to fund new machinery, meet working capital needs, and repay debt, prior to its listing on BSE SME.

RHP DRHP Check Allotment Status

Min Investment

₹1,23,000

Lot Size

1,000 Shares

Price Range

₹115-123

Issue Size (₹ Cr.)

₹27.56 Cr

IPO Type

BSE SME

Key Metrics

Face Value

₹ 10

GMP

₹ 10.0

Subscription

EPS

₹ 9.32

P/E Ratio

13.2 x

RoNW

40.36%

ROE

50.56%

Debt to Equity (₹ Cr.)

0.68

Timeline

IPO Opened09/07/2025Wednesday

IPO Closed11/07/2025Friday

Allotted14/07/2025Monday

Refunded15/07/2025Tuesday

Listed16/07/2025Wednesday

Strengths

Diverse Product Range - The company manufactures a variety of pharmaceutical and nutraceutical products including tablets, capsules, ointments, and syrups.
Export Presence - Asston serves both domestic and international markets, exporting products to over 10 countries across Africa and Asia.
Experienced Management - Promoters and leadership bring decades of experience in pharmaceuticals, supporting strategic growth and compliance.
In-House R&D - Strong formulation and development capabilities help in creating customized products for different markets and client needs.
Healthy Profit Margins - The company has shown solid profitability in recent years with strong operating margins and return ratios.

Weaknesses

Client Dependency - A large share of revenue comes from a few clients, making the business vulnerable to order fluctuations.
Single Manufacturing Unit - Operations are concentrated in one facility, increasing risk from any disruption at that location.
High Working Capital Requirement - The company’s business model requires significant investment in inventory and receivables.
Limited Brand Visibility - Being primarily a contract manufacturer, it has low brand recognition in the end-consumer market.
Moderate Debt Levels - While not excessive, the company still carries debt that may limit future borrowing capacity or affect margins if interest rates rise.